

1702.401600

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
GUSTAV GAUDERNACK, ET AL.	)	: Examiner: Unassigned
Int'l Appln. No.: PCT/NO99/00141	)	: Group Art Unit: Unassigned
Int'l Publn. No.: WO 99/58564	)	:
U.S. Appln. No.: 09/674,913	)	:
Nat'l Entry Date: November 8, 2000	)	:
For: FRAMESHIFT MUTANTS OF	)	May 25, 2001
BETA-AMYLOID PRECURSOR	)	:
PROTEIN AND UBIQUITIN-B	)	:
AND THEIR USE	)	:

**BOX PCT**

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES  
(FORM PCT/DO/EO/920) ("SEQUENCE LISTING NOTIFICATION")

Sir:

In response to the SEQUENCE LISTING NOTIFICATION  
mailed March 27, 2001, enclosed please find a computer readable  
form and a paper copy of the Sequence Listing under 37 C.F.R.  
§ 1.821-1.825, and a Statement Under 37 CFR §1.821(f)  
specifying that the Sequence Listing information recorded in  
computer readable form on the attached diskette is identical to  
the written Sequence Listing.

Although Applicants have responded to the SEQUENCE LISTING NOTIFICATION as noted above, Applicants wish to make the record clear that a computer readable copy and a paper copy of the Sequence Listing under 37 C.F.R. § 1.821-1.825 were filed with the U.S. Patent and Trademark Office on November 8, 2000, on the date of National Entry, together with the application, the National Fee and other items. A copy of the stamped postcard is enclosed as proof of this fact. However, Applicants now recognize that the Sequence Listing that was filed on November 8, 2000 may not be in proper form under the U.S. sequence rules set forth in 37 CFR §§ 1.821-1.825. Accordingly, the computer readable copy and paper copy of the Sequence Listing being submitted herewith have been reformatted in order to place the Sequence Listing in better form under the U.S. sequence rules. By reformatting the Sequence Listing, Applicants submit that no new matter has been added.

Although Applicants believe that no additional fee needs to be filed in connection with this paper, the Commissioner is nonetheless authorized to charge any additional fees or credit any overpayment associated with this paper to Deposit Account No. 06-1205. A duplicate copy of this Response is attached for that purpose.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



\_\_\_\_\_  
Attorney for Applicants

Registration No. 2010

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200  
NMD/llp

1702.401600



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
GUSTAV GAUDERNACK, ET AL. ) : Examiner: Unassigned  
Int'l Appln. No.: PCT/NO99/00141 ) : Group Art Unit: Unassigned  
Int'l Publn. No.: WO 99/58564 ) :  
U.S. Appln. No.: 09/674,913 ) :  
Nat'l Entry Date: November 8, 2000 ) :  
For: FRAMESHIFT MUTANTS OF ) : May 25, 2001  
BETA-AMYLOID PRECURSOR ) :  
PROTEIN AND UBIQUITIN-B ) :  
AND THEIR USE ) :

**BOX PCT**

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER  
35 U.S.C. 371 IN THE U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)

Sir:

In response to the NOTIFICATION OF MISSING  
REQUIREMENTS UNDER 35 U.S.C. 371 mailed March 27, 2001,  
enclosed please find an executed Combined Declaration and Power  
of Attorney form, together with the surcharge fee of \$130.00.  
Also enclosed is a copy of the NOTIFICATION OF MISSING  
REQUIREMENTS UNDER 35 U.S.C. 371. As to item 5 of the  
NOTIFICATION OF MISSING REQUIREMENTS indicating that Applicants  
have not submitted the required sequence listing pursuant to 37  
CFR §§1.821-1.825, and directing Applicants' attention to  
document PCT/DO/EO/920 ("Sequence Listing Notification"),

Applicants direct the Examiner's attention to the attached Response to the Sequence Listing Notification. This second Response is directed to the "missing requirement" identified in item 5.

The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 06-1205. A duplicate copy of this Response is attached for that purpose.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Attorney for Applicants

Registration No. 30110

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

NMD/llp

Commissioner for Patents  
Washington, D.C. 20231

Date 5/25/01  
Mo. Day Yr.

Atty. Docket 1702.401600

Application No. 09/674,913

(PET/NOA/00141)  
US Abat'l. Stage

Sir:

Kindly acknowledge receipt of the accompanying:

☒ Response to Official Action. Notification of Missing Requirements dated March 27, 2001

☒ Check for \$ 130.00 (claims fee) surcharge

☐ Petition under 37 CFR 1.136 and Check for \$ \_\_\_\_\_

☐ Notice of Appeal and Check for \$ \_\_\_\_\_

☐ Information Disclosure Statement, PTO-1449 and


☒ Copy Nov. 8, 2000 stamped postcard

☒ Executed Decl. / Copy form PTO 1001E01905

☒ Response to Notification to Comply with Requirements for Patent Applica.

☒ Other (specify) containing nucleotide sequence... (paper copy of sequence listing)

by placing your receiving date stamp hereon and returning to deliverer.



Atty. NMD/lep

Due Date 5/27/01  
Mo. Day Yr.

FCIS-D-00

1702.401600

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	:	Examiner: Unassigned
GUSTAV GAUDERNACK, ET AL.	)	
	:	Group Art Unit: Unassigned
Int'l Appln. No.: PCT/NO99/00141	)	
	:	
Int'l Publn. No.: WO 99/58564	)	
	:	
U.S. Appln. No.: 09/674,913	)	
	:	
Nat'l Entry Date: November 8, 2000	)	
	:	
For: FRAMESHIFT MUTANTS OF	)	May 25, 2001
BETA-AMYLOID PRECURSOR	:	
PROTEIN AND UBIQUITIN-B	)	
AND THEIR USE	:	

**BOX PCT**

Commissioner For Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R § 1.821(f)

Sir:

Applicants hereby submit that the Sequence Listing information recorded in computer readable form on the attached diskette is identical to the paper copy of the Sequence Listing filed concurrently herewith.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,



Registration No. 30110  
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York, 10112-3801  
Facsimile: (212) 218-2200

NMD\llp





RECEIVED  
UNITED STATES PATENT

APR 2001

TRADEMARK OFFICE

MAY 25 2001

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.

09/674913

FIRST NAMED APPLICANT

DERNACK

ATTY. DOCKET NO.

G

1702.401600

INTERNATIONAL APPLICATION NO.

PCT/NO99/00141

I.A. FILING DATE

30 APR 99

PRIORITY DATE

08 MAY 98

DATE MAILED:

27 MAR 2001

FITZPATRICK CELLA HARPER & SCINTO  
30 ROCKEFELLER PLAZA  
NEW YORK, NY 10112 3801

FILE NO. 1702.4016

ATTORNEY JHB


DUE DATE 4/23/01

DOCKETED 4/26/01

**NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):

- ☒ U.S. Basic National Fee. ☐ Indication of Small Entity Status.  
☒ Copy of the international application. ☐ Translation of the international application into English.  
☐ Oath or Declaration of inventors(s). ☐ Translation of Article 19 amendments into English.  
☐ Copy of Article 19 amendments. ☐ Other:  
☒ Priority Document.  
☒ The International Preliminary Examination Report in English and its Annexes, if any.  
☐ Translation of Annexes to the International Preliminary Examination Report into English.



2. ☒ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

- ☐ U.S. Basic National Fee. ☐ Copy of the international application.

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.  
☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.  
☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).  
☒ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.  
☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.  
☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$\_\_\_\_\_ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

**ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.

7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

**A copy of this notice *MUST* be returned with this response.**

Enclosed: ☐ PCT/DO/EO/917  
☐ PTO-875

☐ Notice of Defective Translation  
☒ PCT/DO/EO/920

Winston M Alvarado

FORM PCT/DO/EO/905 (March 2001)

Telephone: 703-305-6424